- Home
- XTNT vs ANVS Comparison
XTNT vs ANVS Comparison
Compare XTNT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XTNT | ANVS |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 69.1M |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | XTNT | ANVS |
|---|---|---|
| Price | $0.52 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.00 | ★ $13.50 |
| AVG Volume (30 Days) | 100.5K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 39.39 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $53,337,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.30 | N/A |
| P/E Ratio | $18.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $1.54 |
| 52 Week High | $0.95 | $5.50 |
Technical Indicators
Market Signals| Indicator | XTNT | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 57.36 |
| Support Level | $0.44 | $2.29 |
| Resistance Level | $0.67 | $2.67 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 42.71 | 79.80 |
Price Performance
Historical ComparisonAbout XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.